Aprepitant Amorphous Solid Dispersion Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aprepitant's poor solubility in water poses a significant challenge in developing pharmaceutically acceptable compositions, as existing methods like particle size reduction and cyclodextrin complexation do not provide a stable and economically viable solution for enhanced solubility and bioavailability.
Innovation Solution
An amorphous solid dispersion of Aprepitant with polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, combined with lactose as a diluent, disintegrants, glidants, and lubricants, is formulated to enhance solubility and stability, using methods like spray drying and melt extrusion to maintain the active ingredient in an amorphous state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If particle size reduction is used to enhance solubility, then dissolution rate is improved, but manufacturing complexity and cost increase due to nanoparticle formulation requirements
Solution Approach 1:
The patent uses composite materials by formulating aprepitant with solubility-enhancing excipients (such as surfactants, cosolvents, or cyclodextrins) to create a composite pharmaceutical composition. This approach enhances solubility without requiring nanoparticle reduction, thereby avoiding the manufacturing complexity associated with nanotechnology while achieving improved dissolution rates through the synergistic effects of the composite formulation.
2Productivity
If cyclodextrin complexation is used to improve solubility, then bioavailability is enhanced, but manufacturing cost and process complexity increase
Solution Approach 1:
The patent applies parameter changes by modifying the physical-chemical parameters of aprepitant through formulation with solubility-enhancing excipients. Instead of using cyclodextrin complexation, the invention changes parameters such as pH, solubility product, and molecular interactions through alternative excipients, achieving enhanced bioavailability while reducing manufacturing cost and process complexity associated with cyclodextrin-based approaches.
3Productivity
If amorphous solid dispersion is used to enhance solubility, then dissolution rate is improved, but formulation stability becomes challenging to maintain
Solution Approach 1:
The patent applies local quality by creating a formulation where solubility enhancement is achieved through localized interactions between aprepitant and specific excipients (such as surfactants or cosolvents) rather than requiring the entire formulation to be in an amorphous state. This approach maintains the crystalline stability of the drug substance while achieving dissolution rate enhancement through localized solubility modification at the drug-excipient interface, thereby resolving the contradiction between dissolution rate and formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion significantly improves Aprepitant's solubility and bioavailability, providing a stable and cost-effective immediate release formulation with enhanced dissolution rates and long-term stability, avoiding unwanted impurities and ensuring product effectiveness.
Implementation Method 1
An amorphous solid dispersion of Aprepitant with polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer
Implementation Method 2
using methods like spray drying and melt extrusion to maintain the active ingredient in an amorphous state
Implementation Method 3
using methods like spray drying and melt extrusion to maintain the active ingredient in an amorphous state
Data Source
AI summary
Amorphous solid dispersions significantly improve solubility problems associated with Aprepitant. Finished dosage forms as well as processes for the preparation thereof are provided.